SGLT2 Inhibitors for Longevity: What the Evidence Says in 2025

What Are SGLT2 Inhibitors and Why Do Longevity Researchers Care About Them?

SGLT2 inhibitors block sodium-glucose co-transporter 2 in the proximal tubule, forcing the kidney to excrete roughly 60, 90 grams of glucose per day regardless of insulin. That glucose loss creates a mild, sustained caloric deficit and shifts hepatic metabolism toward fatty-acid oxidation and ketone production. Both shifts mimic the metabolic signature of caloric restriction, the most reproducible life-extension intervention in animal models. Caloric-restriction mimicry is the central mechanistic argument for SGLT2s as geroprotectors.

The three agents with the most human outcomes data are empagliflozin (Jardiance), dapagliflozin (Farxiga), and canagliflozin (Invokana). Each binds the same transporter but with slightly different selectivity profiles, renal handling, and trial populations. Researchers noticed early that the cardiovascular benefits appeared too large and too fast to be explained by glycemic control alone, which prompted the mechanistic work on aging pathways that now drives the longevity interest.

Cellular aging requires four converging insults: excess mTORC1 signaling, falling NAD+ availability, rising oxidative stress, and chronic low-grade inflammation. SGLT2 inhibitors appear to touch at least three of those four nodes, which is unusual for a single drug class and explains why cardiologists, nephrologists, and now longevity clinicians are prescribing them in populations who do not have diabetes.

The Cardiovascular Outcome Trials: Where the Hard Numbers Live

The mortality data on SGLT2 inhibitors are among the most striking in modern cardiology.

EMPA-REG OUTCOME enrolled 7,020 adults with type 2 diabetes and established cardiovascular disease. Empagliflozin 10 mg or 25 mg daily reduced the composite of CV death, nonfatal MI, or stroke by 14% (HR 0.86 to 95% CI 0.74, 0.99, P=0.04 for superiority). CV death specifically fell by 38% (HR 0.62, P<0.001). All-cause mortality dropped by 32% (HR 0.68, P<0.001). The speed of divergence in survival curves, within the first few months, suggested a hemodynamic mechanism rather than slow plaque regression.

DAPA-HF tested dapagliflozin 10 mg in 4,744 patients with heart failure with reduced ejection fraction, including 42% without diabetes. The primary endpoint of worsening heart failure or CV death was reduced by 26% (HR 0.74 to 95% CI 0.65, 0.85, P<0.001). The benefit was nearly identical in the subgroup without diabetes, which was the first major signal that SGLT2s might work outside their approved metabolic indication.

EMPEROR-Reduced and EMPEROR-Preserved added empagliflozin data in both reduced and preserved ejection-fraction heart failure, and DAPA-CKD demonstrated that dapagliflozin slows eGFR decline even in non-diabetic chronic kidney disease. DAPA-CKD (N=4,304) showed a 44% reduction in the composite of sustained 50% eGFR decline, end-stage kidney disease, or renal or CV death.

These are not surrogate-endpoint trials. They measure death. That distinction matters when evaluating any longevity intervention.

Mechanistic Pathways Relevant to Aging

Four pathways explain most of the current scientific interest.

AMPK activation and mTORC1 suppression. SGLT2 inhibitors activate AMP-activated protein kinase, the cellular energy sensor that signals caloric scarcity. AMPK then suppresses mTORC1, the same complex inhibited by rapamycin. A 2021 review in Ageing Research Reviews detailed how SGLT2-mediated AMPK/mTOR modulation parallels the longevity signaling seen with caloric restriction in multiple species.

Ketone signaling. By promoting hepatic ketogenesis (beta-hydroxybutyrate typically rises to 0.3 to 0.5 mmol/L on therapeutic SGLT2 doses), these drugs provide the heart and brain with a metabolically efficient fuel and activate HDAC inhibitor pathways that reduce NLRP3 inflammasome activity. Beta-hydroxybutyrate specifically inhibits the NLRP3 inflammasome, lowering IL-1beta and IL-18. Chronic low-grade inflammation, sometimes called inflammaging, is a central driver of age-related organ deterioration.

Oxidative stress reduction. SGLT2 inhibitors lower NADPH oxidase activity in the proximal tubule and in cardiomyocytes, reducing mitochondrial superoxide production. A 2020 paper in Redox Biology using human cardiac samples showed that empagliflozin reduced mitochondrial ROS by approximately 30% in cells exposed to high-glucose conditions.

Autophagy induction. The AMPK activation described above also phosphorylates ULK1, the primary autophagy initiator. Autophagy clears damaged organelles and misfolded proteins, two accumulation processes that track closely with cellular senescence.

None of these mechanisms have been confirmed to extend lifespan in randomized human trials. The mechanistic case is compelling; the direct longevity evidence in healthy non-diabetic humans is still pending.

SGLT2 Inhibitors vs. Rapamycin (Sirolimus)

Rapamycin is the most direct pharmacological mTOR inhibitor available. It was discovered in a soil sample from Easter Island in 1972 and approved by the FDA as an immunosuppressant for organ transplant recipients. Off-label longevity use at low intermittent doses (typically 5 to 10 mg once weekly, far below transplant doses) has grown rapidly, driven partly by data from the Interventions Testing Program (ITP), which showed that rapamycin extended median lifespan in male and female mice by 9 to 14% even when started late in life. The original ITP rapamycin findings were published in Nature in 2009.

The PEARL trial is testing low-dose rapamycin (5 mg or 10 mg weekly) in healthy older adults aged 50, 85, with results expected in 2026. No equivalent completed lifespan RCT exists yet for SGLT2 inhibitors in non-diabetic populations.

Comparing the two mechanistically, rapamycin suppresses mTORC1 directly via FKBP12 binding, while SGLT2 inhibitors suppress it indirectly through AMPK. The indirect route may carry lower risk of mTORC1-independent effects, including the insulin resistance and immune suppression seen with rapamycin. Practical risk profiles differ substantially. SGLT2 inhibitors carry risks of genital mycotic infections (incidence roughly 8 to 10% in women), urinary tract infections, and euglycemic DKA. Rapamycin at low doses carries risks of mouth sores, hyperlipidemia, and theoretical immune impairment. Neither profile is trivial for healthy adults.

HealthRX Longevity Drug Comparison Framework (for non-diabetic, non-HF adults):

| Drug | Strongest Human Evidence | Main Longevity Mechanism | Approved Off-Label Longevity RCT | |---|---|---|---| | Empagliflozin/Dapagliflozin | CV mortality, HF, CKD outcomes (RCTs) | AMPK/mTORC1, ketones, NLRP3 | No | | Rapamycin (sirolimus) | Transplant outcomes; mouse ITP data | Direct mTORC1 inhibition | PEARL trial ongoing | | Metformin | UKPDS, observational data | AMPK activation | TAME trial ongoing | | NR / NMN | Small short-term RCTs in humans | NAD+ restoration | No completed lifespan RCT |

Metformin Off-Label Longevity: The TAME Trial Standard

Metformin is the most studied potential longevity drug in humans by publication volume. It also activates AMPK, shares overlap with SGLT2 mechanisms, and costs less than USD 10 per month. Epidemiological data from the UKPDS extension suggested that early metformin use in overweight patients with T2D reduced all-cause mortality by 36% over 10 years compared to diet alone, though confounding limits interpretation.

The TAME (Targeting Aging with Metformin) trial, funded by the American Federation for Aging Research, enrolled approximately 3,000 adults aged 65, 79 without diabetes at 14 US sites. The primary endpoint is a composite of time to first occurrence of a major chronic disease (cardiovascular event, cancer, dementia) or death. TAME is the first FDA-accepted trial to use aging itself as the indication, setting a regulatory precedent for future longevity drug submissions. Results are expected by 2027.

No analogous completed trial of an SGLT2 inhibitor in healthy non-diabetic older adults exists at the time of this writing. The EMPA-KIDNEY and DAPA-CKD populations overlap with the aging phenotype (CKD and heart failure are age-enriched conditions), but they are not longevity trials by design.

A frequently asked question is whether SGLT2 inhibitors should be added to metformin in an off-label longevity stack. Some longevity-oriented clinicians are doing this, citing additive but non-overlapping mechanisms. That combination has not been tested in a longevity RCT.

Nicotinamide Riboside (NR) and Nicotinamide Mononucleotide (NMN): Where Do They Fit?

NAD+ (nicotinamide adenine dinucleotide) is a cofactor required for mitochondrial energy production, DNA repair via PARPs, and sirtuin deacetylase activity. NAD+ tissue levels fall roughly 50% between age 40 and 80 in humans, a finding consistently observed in muscle biopsy data. A 2023 paper in Nature Aging confirmed age-related NAD+ decline in human skeletal muscle and showed partial restoration with oral NR 1 to 000 mg/day over 21 days.

NR and NMN are oral precursors that raise intracellular NAD+. NR is the more studied of the two in humans. The CANUE trial (NCT03327029) tested NR 1 to 000 mg/day in healthy middle-aged adults and found significant increases in blood NAD+ metabolites but no statistically significant improvement in insulin sensitivity, blood pressure, or arterial stiffness at 12 weeks. That trial result was published in Cell Reports Medicine in 2020.

NMN data in humans are more limited. A 2021 Japanese placebo-controlled trial (N=25) of NMN 250 mg/day for 12 weeks showed increased muscle NAD+ metabolites and improved gait speed in older men, suggesting a functional benefit, but the sample was too small to draw definitive conclusions. The study was published in NPJ Aging and Mechanisms of Disease.

Neither NR nor NMN has cardiovascular mortality or hospitalization data comparable to SGLT2 inhibitors. They are supplements, not prescription drugs, and the regulatory pathway for a longevity claim is essentially absent. The mechanistic rationale (restoring NAD+ to support sirtuins and PARPs) is real and biologically plausible. The human functional benefit remains modest and inconsistent across trials.

One key distinction: NR and NMN address a different aging node (NAD+ depletion) than SGLT2 inhibitors (mTOR/AMPK/inflammation), so they could theoretically be complementary rather than competing interventions.

Off-Label SGLT2 Prescribing in Non-Diabetic Adults: Current Clinical Practice

"The evidence base for SGLT2 inhibitors in heart failure without diabetes is now sufficient to consider these drugs for older adults at high cardiovascular or renal risk, regardless of glycemic status," according to the 2022 AHA/ACC Heart Failure Guideline update, which gave dapagliflozin and empagliflozin a Class IIa recommendation for HFpEF. The full guideline text is available through the American Heart Association.

Outside of documented heart failure or CKD stage G3+, prescribing SGLT2 inhibitors purely for longevity remains off-label and investigational. The FDA has not approved any drug for the indication of aging or longevity extension. Clinicians at longevity-focused practices typically require at minimum: fasting glucose and HbA1c to exclude undiagnosed diabetes or prediabetes, a baseline eGFR (most clinicians avoid initiating if eGFR <45 mL/min/1.73m²), urinalysis, and a shared decision-making conversation about the risks.

The genital mycotic infection rate is clinically significant in women (8 to 10% in trial populations) and warrants explicit counseling. Euglycemic DKA, while rare at approximately 0.1, 0.5 per 100 patient-years, can be life-threatening and presents without the classic hyperglycemia that normally triggers clinical suspicion. Patients on low-carbohydrate or ketogenic diets face higher DKA risk and should either avoid SGLT2 inhibitors or be counseled to hold the drug during prolonged fasting, surgery, or acute illness.

The Endocrine Society's 2023 Clinical Practice Guideline on pharmacological approaches to healthy aging does not yet endorse SGLT2 inhibitors for longevity in non-diabetic adults, citing insufficient long-term safety data in that population. The guideline is available at endocrine.org.

Biomarkers Used to Track SGLT2 Longevity Effects in Clinical Practice

Longevity-oriented clinicians use several proxy markers to gauge whether an SGLT2 inhibitor is producing the expected physiological effects in a non-diabetic patient.

Ketone level. A fasting beta-hydroxybutyrate of 0.2 to 0.6 mmol/L confirms SGLT2-mediated ketogenesis. Values above 1.0 mmol/L in a non-diabetic patient warrant reassessment of diet and dose.

HbA1c and fasting glucose. Should remain in normal ranges. A fall in HbA1c below 5.2% in a non-diabetic patient may indicate excessive glycosuria and warrants dose review.

eGFR trend. An initial 5 to 10% dip in eGFR within the first 2 to 4 weeks is expected (hemodynamic effect) and does not indicate nephrotoxicity. A fall greater than 30% or sustained decline warrants drug discontinuation.

High-sensitivity CRP. Some clinicians track hsCRP as a proxy for the anti-inflammatory effect. Reductions of 15 to 25% have been reported in small observational series, though there is no validated target.

Blood pressure. Systolic BP typically falls 3 to 5 mmHg on empagliflozin or dapagliflozin, a modest but additive benefit in patients managing cardiometabolic risk factors.

Body weight. A loss of 1.5 to 3 kg over the first 12 weeks from glycosuria is expected. Absence of any weight change may suggest poor adherence or atypical renal glucose handling.

Dose Selection and Practical Prescribing Considerations

Most outcomes data come from two doses: empagliflozin 10 mg/day (the dose used in EMPA-REG OUTCOME's primary mortality analysis) and dapagliflozin 10 mg/day (used in DAPA-HF and DAPA-CKD). The 25 mg empagliflozin dose showed similar CV mortality reduction to 10 mg in EMPA-REG OUTCOME but slightly more weight loss and slightly higher DKA risk in subgroup analyses.

For off-label longevity use in non-diabetic adults, most clinicians start at the lowest approved dose and reassess at 12 weeks. Canagliflozin (100 to 300 mg/day) has similar mechanistic properties but higher rates of lower-limb amputation observed in CANVAS (HR 1.97 to 95% CI 1.41, 2.75) and is generally not the preferred agent for longevity prescribing given that signal. The CANVAS amputation finding is documented in the FDA label and the original NEJM publication.

Drug interactions relevant to longevity polypharmacy: SGLT2 inhibitors may modestly increase lithium levels (case reports only), and concurrent loop diuretics increase dehydration and electrolyte risk. The combination of SGLT2 inhibitors with metformin is FDA-approved for T2D and is the most common combination seen in longevity practices that stack both.

What the Longevity Field Still Needs to Know

The central unanswered question is whether SGLT2 inhibitors extend lifespan or healthspan in adults who do not have diabetes, heart failure, or CKD. The outcome trials established benefit in high-risk populations, but the absolute risk reductions in those populations are large partly because baseline risk is high. In a healthy 55-year-old with no cardiovascular disease and normal kidney function, the absolute benefit of SGLT2 inhibition over 5 years is unknown and may be small.

A registered clinical trial, NCT05071950 (EMPA-KIDNEY extension), is tracking eGFR trajectories and survival in CKD patients, and its follow-up data through 2026 may shed light on very-long-term effects. No trial has randomized healthy non-diabetic adults to an SGLT2 inhibitor for a primary endpoint of all-cause mortality or biological age.

Until that trial exists, the strongest honest statement a clinician can make is this: SGLT2 inhibitors have the most strong human mortality data of any drug currently used off-label for longevity. That distinction is meaningful but does not constitute proof of longevity benefit in healthy adults. Start with documented indications when they exist. For purely preventive use, shared decision-making, written informed consent, and close monitoring are non-negotiable.

Empagliflozin 10 mg/day, taken with eGFR monitoring every 6 months and an annual HbA1c check, remains the most defensible starting point for a non-diabetic adult aged 50+ who has chosen off-label SGLT2 therapy after a full informed-consent conversation with a licensed prescriber.